Navigation Links
Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine

WALTHAM, Mass., Feb. 7 /PRNewswire/ -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today that its co-founder and CEO Mitchell P. Fink M.D. was presented with the Distinguished Investigator Award from the American College of Critical Care Medicine during the 37th Critical Care Congress of the Society of Critical Care Medicine held February 2-6 in Honolulu, Hawaii.

The prestigious recognition was awarded to Dr. Fink for his pioneering research related to the pathogenesis and treatment of sepsis, a serious medical condition characterized by widespread inflammation, due to infection.

Dr. Fink was the Founding Chairman of the Department of Critical Care Medicine at the University of Pittsburgh, the first such department at a medical school in the United States. Dr Fink also held other University appointments including Professor of Pharmacology, the Watson Professor of Surgery, and Associate Vice-chancellor for Translational Research. Dr. Fink's academic research program was continuously funded by the National Institutes of Health for more than 20 years.

The Society of Critical Care Medicine, which bestowed the honor to Dr. Fink, is the leading professional organization dedicated to ensuring excellence and consistency in the practice of critical care medicine. With more than 13,000 members worldwide, the Society is the only professional organization devoted exclusively to the advancement of multi-professional intensive care through excellence in patient care, professional education, public education, research and advocacy.

Dr. Fink is an author or co-author of more than 250 peer-reviewed scientific publications, has edited or co-edited 13 textbooks and is currently an Associate Editor for two highly regarded scientific journals: the Journal of Pharmacology and Experimental Therapeutics and the Journal of Leukocyte Biology.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Waltham, Massachusetts. Logical Therapeutics is developing drugs to treat a variety of medical conditions that are caused by or are associated with excessive inflammation, including various forms of arthritis, obesity and type 2 diabetes mellitus. For more information on Logical Therapeutics, visit the company's website at or by email at

SOURCE Logical Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
2. Neurobiological Technologies Sets Date for Second Quarter Financial Results
3. Montana State University lab gives early warnings about biological invaders
4. Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Womens Biological Clock
5. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. The Tauri Group LLC Awarded U.S. Department of Homeland Security Chemical and Biological Early Detection Systems Program Office Support Contract
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
10. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
11. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
Post Your Comments:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):